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Executive Summary:
This paper has been prepared as a contribution to analysis and discussion of the development of an international regime on access to genetic resources and benefitsharing under the Convention on Biological Diversity (Decision VII/19).
The paper provides a review and preliminary assessment of the implications of intellectual property claims in relation to microorganisms for the development of an international regime. The review is divided into two sections which may be read independently. Section I examines the public policy implications of intellectual property claims over microorganisms which form part of access and benefit-sharing agreements between protected area authorities and public or private bodies. Section II presents the outcomes of research on global trends in intellectual property claims over microorganisms.
Section I considers growing interest in the potential of access and benefit-sharing agreements between protected area authorities and private bodies for the promotion of conservation objectives in protected areas. The discovery of a microorganism Thermus aquaticus in Yellowstone National Park in the United States and identification of an enzyme Taq DNA polymerase which has proved vital in the arena of biotechnology serves as an exemplar for the potential of access and benefit-sharing arrangements involving protected areas. A review of the litigation surrounding the enzyme reveals a series of wider public policy issues that may merit further consideration. These issues include: a) the impacts of patenting of biological research tools on research and innovation; b) the implications of the commercialisation of public sector research for protected area authorities; c) risks of involvement in patent litigation and cases of inequitable conduct; d) potential conflicts between agreements permitting patenting of components of organisms within protected areas and requirements for protection of the public domain and resources covered under the common law public trust doctrine; e) a need to clarify the meaning of the public domain and the public trust doctrine in light of international human rights obligations relating to indigenous peoples and local communities and the existence of multiple overlapping ownership and/or sovereign rights.
The review recommends a deliberative, participatory and evidence based approach to the consideration of access and benefit-sharing arrangements involving protected areas including scientific and economic analysis of the potential impacts of intellectual property claims over DNA, amino acids, and proteins such as enzymes upon public welfare. However, a major constraint in assessing the implications of the requirements of international intellectual property agreements and trade related agreements for the development of an international regime is a lack of effective methodologies to track patent claims relating to microorganisms. As a contribution to methodological development, the review presents the results of two types of search of the European Patent Office esp@cenet "worldwide" database which incorporates approximately 36,165,421 industrial property publications from 73 national patent offices, four regional patent offices and the World Intellectual Property Organisation (for the Patent Cooperation Treaty).
The results of a key word search of patent publication titles and abstracts for the term "microorganism" suggests that international demand for patent protection (measured in terms of publications) rose to approximately 6,915 patent publications between 1990 and 2000 rising to approximately 10,024 publications if preliminary data for 2001 to 2003 is taken into account. However, the key word search methodology is confined to the titles and abstracts of patent publications available in English and does not provide an accurate indicator of international demand for patent protection. A superior approach to mapping international demand is provided by the International Patent Classification (IPC) system which provides a higher level of data capture. A search of the esp@cenet worldwide database for the main sub-class relating to microorganisms, C12N (Microorganisms or In considering this disparity the review highlights issues surrounding the definition of "microorganisms" under international instruments and notes that patent claims in relation to microorganisms are characterised by publications that may not generally be regarded as "microorganisms", notably plant, animal and human DNA (deoxyribonucleic acid). The review concludes by highlighting the implications of such trends for the scope of an international regime and recommends further methodological development in tracking intellectual property claims in relation to microorganisms.
Introduction:
The Global Biodiversity Outlook estimates that there are approximately 1,000,000 species of bacteria (Archaebacteria and Eubacteria) of which 4,000 are thought to have been described. 1 There are also approximately 600,000 species of Protoctists (algae, protozoa, etc.) of which 80,000 are thought to have been described. GRAIN (1999 microorganisms. Microorganisms are also a particular focus of attention for public and private genome mapping projects. 8 Concerns in connection with the rise of intellectual property protection over microorganisms can be briefly summarised as follows:
a) The ethics of patenting life-forms; b) The eligibility of such organisms for patent protection on the grounds of whether they are new (or novel), involve an inventive step (are non-obvious) and susceptible to industrial application (utility); c) The terms and conditions of bioprospecting arrangements between companies and developing country institutions, and indigenous peoples and local communities, and; d) The longer term implications of the temporary enclosure of the world's microorganisms through patent grants for the promotion of research and innovation.
Bioprospecting for microorganisms and so-called "extremophiles" aided by discoveries such as "Conan the Bacterium" (Deinococcus radiodurans) has recently risen to scientific, public and policy attention. 9 In particular, the exploitation of microorganisms and microbial resources has drawn attention to the potential of access and benefit-sharing arrangements in protected areas to generate revenue and other potential benefits. In contrast, wider trends in the patenting of microorganisms and the public policy implications of such trends have received less attention.
The review begins by examining a bioprospecting agreement involving microorganisms within a protected area as a contribution to identifying the public policy issues surrounding access and benefit-sharing agreements involving intellectual property claims. The review then turns to the analysis of the implications of global trends in the patenting of microorganisms. 
I. Microorganisms and Protected Areas:
International attention has been drawn to the economic importance of microorganisms as a result of an historic case from Norway. In 1969 a scientist working for the Switzerland based Sandoz company collected soil samples in the Hardangervidda mountains while on holiday. 10 The samples were found to contain a fungus, Tolypocladium inflatum within which a compound which came to be known as Cyclosporin was identified (also known as Cyclosporine). This led to the development of a new and critically important immunosuppressant drug for preventing organ transplant rejection (Sandimmun/Neoral).
11 Following the merger of Sandoz and Ceiba Geigy to form the Novartis Group in 1996 Sandimmun/Neoral was transferred to the new company. This historic pre-CBD example illustrates the potential economic importance of microorganisms and microbial materials as sources of potentially valuable compounds, genes, amino acids and proteins such as enzymes and has led some commentators to suggest that if 2% annual royalties had applied this would have generated revenue of US$24.3 million for Norway in 1997. 13 The Hardangervidda mountains were designated as a national park in 1981 and this has served to highlight the potential of microorganisms and microbial resources as potential sources of revenue for protected areas.
14
More recently, companies have demonstrated growing interest in so-called "extremophiles" in countries such as Canada (among others). 15 Increasingly this extends to protected areas, marine environments, and areas governed under international treaty arrangements (notably Antarctica). 16 These trends have in part been presented as a retreat on the part of companies from the controversies which have surrounded bioprospecting activities in developing countries. 17 trends raise wider public policy issues which can be introduced through reference to the case of the Yellowstone National Park in the United States.
18
Bioprospecting in Yellowstone National Park:
Yellowstone National Park "…is home to an estimated eighty percent of the world's terrestrial geysers and more than half of its thermal features, including hot springs, mud pools, and fumeroles". 19 In 1966 Dr. Thomas Brock accompanied by Hudson Freeze of Indiana University discovered a microorganism Thermus aquaticus (a bacterium) in Mushroom Pool in Yellowstone National Park which was resistant to high temperatures. 20 The microorganism was then deposited in the American Type Culture Collection (ATCC) thus making the discovery publicly available.
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One of the major obstacles for the emerging arenas of biotechnology and genomics in the 1970s and early 1980s was the time consuming process involved in replicating or amplifying DNA (deoxyribonucleic acid) which had to be performed by hand. In 1983 Dr. Kary Mullis, a scientist working for Cetus corporation, conceived of the Polymerase Chain Reaction (PCR) to dramatically increase the speed of DNA replication. 22 This involves a basic three step process: a) denaturation; b) annealing of primers; c) primer extension. 23 In the first step (denaturation) an excess of primer consisting of synthetic nucleotides is mixed with the DNA to be replicated and heated to 98ºC until the two strands of DNA separate. This is then allowed to cool to 60ºC at which point the separated DNA strands begin to stick (or anneal) to the complementary sections of the primer DNA (annealing of primers). During the third step (primer extension) a thermostable enzyme is added and through repeated cycles of heating and cooling multiple copies of the target DNA are created. The strength of this technique is that a single fragment of DNA can be replicated upto one million times in merely 20 cycles of heating and cooling. Dr. Mullis was subsequently awarded the Nobel Prize for his contribution to science in 1993. Thermus aquaticus proved to be central to the success of PCR by providing a thermostable enzyme (Taq DNA polymerase) capable of withstanding the high temperatures required for the PCR process. 25 This technique and the enzyme derived from Thermus aquaticus are commonly used in DNA replication around the world: it is difficult to overstate the importance of both the technique and the enzyme in the arena of biotechnology. 26 The patent on the enzyme was reportedly sold for US$300 million in 1991 and generated an annual revenue of US$100 million for the company concerned. 27 However, Yellowstone National Park did not directly benefit from the revenue generated by the discovery.
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In recognition of the desirability of securing a share of benefits which may arise from research on the resources within Yellowstone National Park, in 1995 the National Park Service (NPS) entered into negotiations to establish a benefit-sharing agreement with Diversa Inc.. 29 Diversa is a biotechnology company formed in 1994 which specialises in bioprospecting for extremophiles. 30 The company expresses a public commitment to the objectives of the Convention on Biological Diversity and has entered into access and benefit-sharing agreements in a number of countries and regions.
31
In 1997 a Cooperative Research and Development Agreement (CRADA) was agreed between the National Park Service (under the Department of the Interior) and Diversa under which the parties agreed to cooperate in researching and documenting the biodiversity of the geysers, hot springs, lakes and other ecosystems within the Park.
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Sample collection in the field would be followed by reproduction in the laboratory, isolation of nucleic acids, cloning and creation of a genetic library. 33 The genetic library would then be screened for enzymes and bioactive molecules for potential commercial development. The libraries would also reportedly be made available to Park scientists.
The Cooperative Research and Development Agreement (hereafter CRADA) is reported to award a non-exclusive license for research and development relating to microbial organisms in Yellowstone for which Diversa agreed to pay an annual fee of an estimated US$20,000.
34 Diversa also agreed to pay royalties to the Park of between 25 The process initially employed an enzyme from E.coli, see ibid., Rabinow 1996. 26 Thermus thermophilus provides an alternative enzyme for the PCR process. The key focus of the case was whether the National Park Service (hereafter NPS) had engaged in public consultation and carried out the necessary environmental impact assessments required under the National Environmental Policy Act (NEPA). 37 Furthermore, the plaintiffs argued that the agreement violated the prohibition on "…sale or commercial use of natural products" under Park Service regulations and the public trust doctrine.
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The NPS sought to defend itself against these allegations by asserting that "…the collection of specimens under the CRADA will amount to taking samples that each contain about a teaspoon of water, sediment, and microbial life". As such any aesthetic and environmental consequences would allegedly be minimal. 39 However, presiding Judge Royce C. Lamberth observed that "…although each sample taken from Yellowstone may be the size of a test tube, the overall impact of the specimen collection authorized by the CRADA and its corresponding permit is not teaspoon-sized."
40 Judge Lamberth went on to observe that:
"There is an undeniable reality that commercial activity is qualitatively different than scientific and educational activity of a similar nature, due to the very different forces and motivations that drive them." 41 Judge Lamberth concluded that the issues raised, required "…intensive deliberation by the defendants, ideally with public-input--precisely the deliberation mandated by Congress through the NEPA…" and ordered:
"…that defendants suspend implementation of the On the 12 th of April 2000, Judge Lamberth issued his final judgement in the case. On this occasion Judge Lamberth found that in practice the National Park Service had correctly interpreted the relevant legislation and regulations. Specifically, he found that the company concerned would not own the organisms they collected and would be required to meet the conditions for normal research permission. 43 Judge Lamberth observed that the CRADA only applied to: "…rights and responsibilities of Yellowstone and Diversa with respect to information and inventions developed after the conclusion of research specimen collection and analysis" (original emphasis). 44 Furthermore, in the absence of such an agreement, "…Yellowstone could not share in any of the potential benefits from Diversa's research. Instead the positive gains from the research would go exclusively to Diversa." 45 On this basis Judge Lamberth concluded that the NPS had correctly interpreted the governing statutes of the Park "…because it would produce direct, concrete benefits to the Park's conservation efforts by affording greater scientific understanding of Yellowstone's wildlife, as well as monetary support for Park programs." 46 Judge Lamberth also concluded that opposition to the proposed agreement on the grounds that this would represent "sale or commercial use" of Park resources in breach of the Park's mandate was not sustainable. In drawing this conclusion, Judge Lamberth referred to the case of Diamond v. Chakrabarty to support the view that the company concerned would not obtain a property right over the specimens as such (per se), or a right to transfer such specimens to third Parties, in contravention of Park regulations. 47 Rather, the Judge concurred with the National Park Service view that there is:
"...a critical distinction between researchers profiting from the sale of the actual specimens themselves, which is prohibited by Section 2.1, and profiting from a future development based on scientific discoveries resulting from research on those resources, which is permitted." 48 On this basis the case was dismissed "with prejudice". The NPS may proceed with the benefit-sharing agreement subject to the provisions of the previous order requiring action including "but not limited to" the preparation of an Environmental Assessment in accordance with the NEPA . 49 The potential attractions of the establishment of access and benefit-sharing agreements between National Park authorities and private companies are apparently, but, as will be seen, deceptively straight-forward. Thus, it is widely recognised that the majority of protected areas around the world are under-funded: the revenue and research capacity building which may potentially result from benefit-sharing agreements with the private sector or Public Research Organisations could potentially play an important role in addressing conservation objectives. 50 Furthermore, as the NPS highlighted, under the prevailing law within the United States, companies or researchers are free to engage in the commercialisation of the results of research carried out on specimens collected within national parks but the parks will receive no direct benefits in the absence of access and benefit-sharing agreements. 51 The extent to which this situation pertains elsewhere in the world is an open question. In considering this important initiative it is also necessary to consider the wider policy implications of intellectual property protection in access and benefit-sharing arrangements that may be established in protected areas. These issues are particularly important in a context in which many protected areas around the world are inhabited and in view of the promotion of protected areas managed by indigenous peoples and local communities under the programme of work on protected areas established by COP7 (Decision VII/28). 54 These implications come into focus through closer attention to the history of Taq DNA polymerase.
The case of Taq DNA Polymerase:
As noted above, the discovery of Thermus aquaticus and an enzyme, Taq DNA polymerase which is stable at the temperatures required for Polymerase Chain Reaction (PCR) has been fundamental to the emergence of biotechnology and genomics. As also noted Taq DNA polymerase serves as an exemplar for the potential of access and benefit-sharing arrangements to generate revenue and other benefits for conservation within national parks. There are three main patents relating to the PCR process and Taq DNA polymerase (hereafter Taq). US patent 4,683,202 filed in October 1985, listing Dr. Kary Mullis as the inventor, refers to the PCR process for "amplifying nucleic acid sequences" and is followed by US patent 4,683,195 filed in February 1986 concerning a "Process for amplifying, detecting, and/or cloning nucleic acid sequences."
In June of 1987 a separate application (US 4,889,818, hereafter '818) was filed by other researchers at Cetus corporation claiming: a) a "Purified thermostable Thermus aquaticus DNA polymerase"; b) the polymerase isolated from Thermus aquaticus, and; c) the same polymerase isolated from a recombinant organism (a bacteria) designed to express the Thermus aquaticus DNA polymerase.
These three patents form the basis for the revenue generated from licensing PCR. As noted above, it is widely reported that the patents were sold to Hoffman-LaRoche Corporation (also known as Roche) for $300 million and are estimated to have generated annual revenue of upto $100 million per year. According to one recent unconfirmed report: "Roche has gained US$2 billion from control of the PCR process." 55 However, the Taq polymerase patent ('818) has also been the focus of over twelve years of ongoing litigation in multiple jurisdictions and is the subject of a US$1 billion lawsuit. ) filed a lawsuit against the US based Promega Corporation alleging breach of contract and infringement of the Taq patent ('818) and related PCR process patents for sales of unlicensed Taq. 58 In response, Promega alleged that the original Taq patent had been obtained from the United States Patent and Trademark Office (USPTO) through "inequitable conduct" consisting of fraudulent claims. Specifically, Promega alleged that the applicants had made a series of misrepresentations to the USPTO in applying for the '818 patent relating to: a) the molecular weight of the Taq enzyme relative to the weight reported by other researchers in the US and Russia in prior publications; b) claims that a key experiment had been conducted at the time of the application that had not in fact been conducted; c) technical claims relating to the distinction between previously published results surrounding Taq polymerase and the enzyme described in the patent application. 64 In Australia, the claims to the Taq polymerase were rejected in November 1997 but reportedly remain subject to appeal.
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The litigation surrounding the legitimacy of the patent over the Taq enzyme is complex, ongoing, and involves high stakes for the parties concerned. This review focuses on the public policy implications arising from disputes in relation to the role of patent protection in access and benefit-sharing arrangements within protected areas. Five main issues stand out.
The first of these is the impact of patents on research and innovation. As noted above, Taq is central to the PCR process. basis. 66 Investigations into the cost of licensed Taq from licensees are also reported to have been met with a refusal to disclose details. 67 However, a 2001 report in Nature suggests that the cost of the polymerase was around 50 cents each time it was used in a single round of genotyping. 68 In contrast, non-licensed Taq was estimated to cost 20-30% less than the licensed enzyme. 69 It has been reported that the cost of unlicensed Taq has fallen to between 10 cents and 16 cents per unit. 70 For publicly funded research organisations employing PCR such cost differentials are significant and are likely to influence the type and amount of research (i.e. genotyping) that can be conducted. This problem was highlighted in a 1996 workshop convened by the United States National Research Council where participants argued that the cost of the polymerase was inhibiting widespread use of diagnostic tests for HIV RNA. Other participants reported that "…the high cost Taq polymerase made many experiments impossible for them" particularly in areas of research that do not attract the levels of funding of human genetic research. 71 Small biotechnology companies were also reported to be affected by the high cost of the Taq enzyme and related PCR technology. The dependency of researchers on the Taq enzyme and other patented enzymes is reflected in the close attention that the patent dispute has received in the scientific press and concerns surrounding the implications of the case for research budgets. 72 In addition to the price of licensed Taq concern has also been expressed about whether those using unlicensed Taq will be pursued for fees if the patent is upheld. It has commonly been assumed that a "research exemption" or "experimental use exemption" applies to non-commercial research and such measures have been introduced in a number of countries. 73 However, in the United States a 2002 decision by the Court of Appeals for the Federal Circuit in Madey v. Duke University held that this exemption does not apply except in the "very narrow form" determined by the court in earlier cases.
A second and related issue surrounds the nature of patent claims in relation to DNA, amino acids, and proteins such as enzymes. The key problem here is that in contrast with other areas of invention addressed by the patent system it is not presently possible to readily "invent around" DNA, amino acids, and proteins such as enzymes. 75 Put simply, DNA molecules and complex folded proteins such as enzymes are presently beyond the skill of human beings to actually create i.e. through synthetic chemistry. 76 Thus, the Taq enzyme was not created or invented by the researchers at Cetus: it is a highly efficient naturally occurring biological catalyst that has been artificially replicated by researchers. 77 It is becoming increasingly clear that the practical effect of permitting patent claims over artificially reproduced DNA and related amino acids, proteins or enzymes is to provide a strong monopoly over the biological make-up (or claimed components) of an organism. When seen from this perspective, in practice a non-exclusive licensing agreement between a national park and a private company which permits patent claims may provide that company with an effective monopoly over the relevant DNA and/or amino acid, protein and enzyme make-up of the organisms concerned.
This has further implications for research. Thus, court documents reveal that Park scientists will be provided with access to the genetic libraries to be developed under the agreement. It is not entirely clear whether such access is confined to scientists employed directly by the National Park Service or may extend to other researchers working within the Park. This raises questions surrounding the criteria that will be employed to determine access to collections made under access and benefit-sharing agreements, potential conflicts of interest, and wider issues surrounding the implications of the increasing commercialisation of research.
Thus, in recognising the importance of the case presented by the NGO coalition, Judge Lamberth drew attention to the critical distinction between the forces which motivate commercial activity and scientific and educational activity. Court documents suggest that all researchers who engage in research within a national park which may lead to commercial developments will be required to sign a CRADA access and benefit-sharing agreement. This raises the question of where the boundary between non-commercial and commercial research will be drawn and by whom? 75 It has been widely observed that in the 20 th Century the boundary between commercial and non-commercial research became increasingly blurred. 78 In the case of the United States, the 1980 Bayh-Dole Act sought to promote innovation by permitting intellectual property claims over the outcomes of federally sponsored research. 79 In response, universities and other Public Research Organisations have engaged in the aggressive pursuit of intellectual property protection in order to generate revenue. 80 The application of this model is now being promoted on a wider level by organisations such as the Organisation for Economic Co-operation and Development (OECD) as part of a process of "Turning Science into Business". 81 Patent claims by Public Research Organisations (PROs), such as universities, commonly take the form of claims not to commercial products but to basic "research discoveries and research tools" such as DNA, amino acids, and proteins such as enzymes. 82 While drawn from the private sector the Taq DNA polymerase '818 patent is in fact cited as a key example of a "research tool" patent. 83 The rise of patenting by universities in the United States has led to a situation in which universities are increasingly in competition with each other and with the private sector and is manifest in the increasing establishment of Technology Transfer Offices and the use of tools such as Material Transfer Agreements (MTAs) to regulate relationships. 84 One consequence of this competition is a lack of willingness to share or publish research results until requirements for patent submission have been met. collaborative research in the pursuit of conservation and/or sustainable use objectives. Furthermore, the increasing commercialisation of publicly funded research may skew research away from important areas of research such as conservation and sustainable use in favour of research directed towards securing revenue.
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A fourth public policy issue surrounds the risk of involvement in patent litigation and/or claims of "inequitable conduct". Thus, if a protected area authority received revenues from a patent found to be unenforceable due to inequitable conduct the authority concerned would have benefited from fraud at the expense of the public. While conservation benefits might offset some of the negative costs to public welfare, the wider negative costs to welfare could be very significant. A further risk, in a highly competitive research environment, is that protected area authorities may face legal challenges where conflicting intellectual property claims arise between researchers. The increasing number of patent disputes involving companies and universities suggests that this risk cannot be readily dismissed and the potential costs of litigation could be considerable.
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A fifth policy issue surrounds the public domain and the public trust doctrine. In the United States the extension of patentability to scientific "discoveries" is commonly attributed to Article 1, Section 8, Clause 8 of the Constitution which seeks "To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries". 88 However, the public domain also enjoys constitutional protection under the First Amendment which establishes that: "Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the Government for a redress of grievances." This constitutional requirement may also potentially be linked with the common law public trust doctrine which "Provides that submerged and submersible lands are preserved for public use in navigation, fishing and recreation and state, as trustee for the people, bears responsibility of preserving and protecting the right of the public to the use of the waters for those purposes."
92 This doctrine has been increasingly extended beyond the realm of submerged and submersible lands to wider "commons" resources and is arguably reflected in the language concerning state sovereignty over biological and genetic resources embodied in the Convention on Biological Diversity.
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It is notable here that the Thermus aquaticus specimen involved in PCR technology was acquired from the American Type Culture Collection (ATCC) and as such was already available in the public domain. Research on the Taq DNA polymerase was then carried out in Russia and the United States by publicly funded researchers which brought the enzyme to the attention of researchers in the private sector. 94 The material was then submitted for patent protection by private sector researchers: the legitimacy of this claim is a focus of ongoing litigation. Whether or not permitting patent claims over microorganisms within the pools of Yellowstone National Park and the underlying genetic components of such organisms could reasonably be classified as restricting "free access to materials already available" and the relationship with the public trust doctrine is clearly a matter for debate.
In considering this question it is useful to return to the court case surrounding the agreement between Yellowstone National Park and the private company, Diversa Inc.. In his final judgement, Judge Lamberth rejected the view that "this case necessarily involves the prohibited sale of natural materials" because:
"…it ignores relevant precedent, which instructs that a substance occurring in nature may not be patented in that form. Diamond 447 U.S. at 313. Instead, to obtain a patent rights [sic], a researcher must bring to a naturally-occurring substance a contribution that is non-obvious, novel and demonstrably useful. the Park service has interpreted its regulations only to allow researchers to study, not sell, Park resources. The CRADA, in turn, accords with the regulations because any "commercial use" flowing from such research is limited to applications or products generated from such scientific study of the resources, not the resources themselves." 95 This conclusion reveals the significant difficulties involved in understanding the nature of patenting in relation to biological organisms and genetic material. Specifically, as noted above, the enzyme found within Thermus aquaticus, and the Taq DNA polymerase enzyme used in PCR are in fact the same. The distinction is that researchers have artificially reproduced the enzyme. The enzyme is however in substantive terms the same enzyme as that which occurs within the organism. While researchers may be able to manipulate the enzyme to certain degrees, such as using the biological equivalent of a pair of scissors (restriction endonucleases) in relation to underlying DNA or other techniques, they are not able to invent it. 96 The significance of this is that researchers who collect samples and artificially reproduce such material for "scientific study" will potentially be exposed to legitimate claims for licensing fees from patent holders. Patent claims surrounding biological and genetic material are commonly constructed using "comprising" language intended to make strong per se (as such) claims over DNA, amino acids and proteins such as enzymes. 97 The practical effect of such measures is to "enclose" the DNA, amino acids and proteins and potential uses of that material within the scope of the patent protection. 98 Permitting patent claims over DNA, amino acids and proteins such as enzymes as "research tools" or within research method claims introduces a requirement for public and private researchers to pay licensing fees for the use of such materials and also permits so-called "reach through" claims over products developed using such tools. 99 When viewed in light of the practical experience of public and private sector researchers with DNA and related patents, the conclusion that "commercial use" does not relate to the "resources themselves" is not convincing and merits re-evaluation.
It is also important to recognise that in contrast with modern experience within the United States, many protected areas around the world are inhabited. In particular, protected areas frequently encompass the lands and territories of indigenous peoples and local communities. The participation of indigenous peoples and local communities and respect for their rights is an important feature of the new programme of work on protected areas adopted by COP7, which:
"Recalls the obligations of Parties towards indigenous and local communities in accordance with Article 8(j) and related provisions and notes that the establishment, management and monitoring of protected areas should take place with the full and effective participation of, and full respect for the rights of, indigenous and local communities consistent with national law and applicable international obligations." 100 As this suggests, determination of what, if any, role intellectual property protection might play in the promotion of access and benefit-sharing arrangements within protected areas that encompass the lands, territories or waters of indigenous peoples and local communities will necessarily involve the participation of indigenous peoples and local communities and consideration of international obligations in the arena of human rights. 101 This will also logically involve clarification of the significance of the public domain and interpretation of the public trust doctrine in the context of international human rights obligations and recognition of indigenous ownership and/or sovereignty over traditional knowledge and biological and genetic materials. 102 The collection of specimens for bioprospecting or other research purposes may also impact upon the sacred sites, lands and waters of indigenous peoples and local communities. 103 These considerations may also be relevant to protected areas which were formerly inhabited, occupied, or used by indigenous peoples and local communities. 104 These issues extend to countries where the residents of protected areas would not fall within the meaning of the term indigenous as employed within international law and the United Nations system or arguably the language of Article 8(j) of the Convention 100 concerning "local communities embodying traditional lifestyles". 105 Thus, the majority of national parks within the United Kingdom are inhabited and one of the specified purposes of the national park system is "…conserving and enhancing the natural beauty, wildlife and cultural heritage of the areas specified…". 106 These purposes also extend to fostering "…the economic and social well-being of local communities within the National Park." 107 However, UK legislation also specifies that "….if it appears that there is a conflict between those purposes, [a National Park authority] shall attach greater weight to the purpose of conserving and enhancing the natural beauty, wildlife and cultural heritage of the area comprised in the National Park." 108 In the case of the United Kingdom it is unclear where access and benefit-sharing agreements involving intellectual property claims would fall in terms of the purposes for which national parks were established. 109 Given that the national park system in the United Kingdom also plays a major role in environmental and scientific education for future generations, changes to the purposes of national parks would raise questions surrounding present and future public attitudes towards national parks if commercial scientific research was to be permitted in such areas. Further questions would arise surrounding the role of park residents and the wider public in determining any modifications to such purposes. 110 As this suggests, growing interest in bioprospecting for microorganisms within protected areas raises wider public policy questions for governments and other participants within debates surrounding access and benefit-sharing and protected areas under the Convention on Biological Diversity. Experience within the United States provides a series of valuable insights into these wider public policy issues. Addressing these issues is likely to require a combination of: a) clarification of the relationship between the public domain and the public trust doctrine in contexts of overlapping rights in protected areas involving the lands and territories of indigenous peoples and local communities; 111 b) analysis of the cost and benefits involved in establishing research agreements which might permit intellectual property claims; c) public participation and consultation, and; d) exploration of potential alternatives to patent protection which might maximise long-term public welfare benefits and mitigate costs to welfare.
112 Above all, this review suggests the need for a deliberative and evidence based approach to determining what role, if any, intellectual property protection might play in access and benefit-sharing agreements with either public or private research organisations in protected areas.
In closing this discussion of the potential role of intellectual property in relation to microorganisms and access and benefit-sharing agreements involving protected areas, it is useful to recall that the Secretariat of the Convention on Biological Diversity has highlighted that a number of guidelines and policies have emerged in response to issues surrounding access to genetic resources and benefit-sharing in relation to microorganisms. These guidelines and policies include: 
) the "CAB International (CABI) Policy on Access to Ex Situ Genetic
Resources", developed by the intergovernmental organisation CAB for issues surrounding receipt, supply, and benefit-sharing surrounding microorganisms within ex situ collections. 113 The CABI policy includes a model Material Transfer Agreement (MTA).
In the private sector companies such as GlaxoSmithKline, Novo Nordisk (now Novo Nordisk and Novozymes), Xenova, Shaman Pharmaceuticals, and Bristol-Myers Squibb have developed policies or 'best practice' in connection with microorganisms. 114 The policies of companies such as Diversa (above), Amgen and Genecorp also merit closer attention. 115 Existing policies and guidelines surrounding microorganisms adopted by Public Research Organisations (PROs), intergovernmental organisations and the private sector could usefully be examined as part of debates concerning the establishment of an international regime and debates surrounding the further development of the Bonn Guidelines. As the discussion provided above suggests a fuller understanding of 111 These issues may perhaps best be addressed under the Working Group on Article 8(j) and related provisions which will collaborate with the Working Group on Access and Benefit-Sharing in the development of an international regime (Decision VII/19, D para. 1). Location: <http://www.biodiv.org./decisions/default.aspx?m=COP-07&id=7756&lg=0>. During COP7 Parties agreed on a potential list of elements for the development of a sui generis system for the protection of traditional knowledge based on the outcomes of deliberations during the 8(j) Working Group with strong participation by indigenous peoples' delegates (see Decision VII/16 H 'Development of elements of sui generis systems for the protection of traditional knowledge, innovations and practices' and Annex). Location: <http://www.biodiv.org./decisions/default.aspx?m=COP-07&id=7753&lg=0>. 112 Ibid., Scotchmer, S 2004 113 UNEP/CBD/WG-ABS/2/2 'Further consideration of outstanding issues related to access and benefit-sharing: Use of terms, other approaches and compliance measures: Note by the Executive Secretary'. Location: <http://www.biodiv.org/doc/meetings/abs/abswg-02/official/abswg-02-02-en.doc>. 114 Ibid., UNEP/CBD/WG-ABS/2/2. 115 Ibid., GRAIN 1999 markets and the research contexts within which intellectual property claims surrounding microorganisms are situated, including licensing practices, is also desirable.
116 This could usefully be linked with the exploration of alternative models directed towards recognising the rights of indigenous peoples and local communities and maximising public welfare gains in relation to conservation, sustainable use, and wider internationally agreed policy goals.
II. Global Status and Trends in Patenting of Microorganisms:
The main international instrument concerned with patent procedure in relation to microorganisms is the 1977 Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (amended 1980). With respect to access and benefit-sharing and biopiracy, in common with other categories of organisms and genetic material, very limited data is presently available on the country of origin of the microorganisms over which protection is sought under the Budapest Treaty. For the purposes of the present review it has not therefore been possible to reach a considered judgement on whether or to what extent: a) patent protection is being sought over specimens from countries of origin that have decided not to extend patent protection to 'microorganisms', or; b) microorganisms are being expropriated from countries which already permit such protection and submitted for patent protection in third countries.
In 1994 the non-governmental Rural Advancement Foundation International (RAFInow the Action Group on Erosion, Technology and Concentration or ETC Group) published a study entitled "Microbial BioPiracy: An Initial Analysis of Microbial Genetic Resources Originating in the South and Held in the North' based on data gathered from the American Type Culture Collection (ATCC).
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The preliminary study identified a total of 874 specimens in the ATCC collection originating from fourteen southern countries. The results of the study are set out in Table Two . To date, as far as it has been possible to establish, such a study has not been repeated. The results of the study are also confined to deposits made prior to the entry into force of the Convention on Biological Diversity and it is unclear how many of the deposits were made under the terms of the Budapest Treaty. However, the preliminary study suggests that deposits were subject to patent grants or claims in 12% of cases.
The ATCC collection and a number of other IDAs have now established online searchable databases. 123 As a contribution to methodological development Table Two includes the results of a search of the ATCC online database using the list of countries employed in the original RAFI/ETC Group study. 124 The results of the search suggest that it is possible to identify the country of origin of deposits using the database. In the case of the countries listed the data suggests that overall deposits within the ATCC from these countries of origin increased by approximately 118% between 1994 and 2004 but varied significantly between countries. This indicative data is offered purely as a contribution to methodological development in mapping status and trends. Given the emerging importance of bioprospecting for microorganisms in 'northern' countries a balanced picture of deposits from Parties to the Convention on Biological Diversity within IDAs is likely to be desirable in the development of any future work. Microorganisms, TRIPS and "TRIPS-plus" agreements:
Article 27.3 (b) of the TRIPS agreement introduces a requirement for member states of the WTO to provide patent protection for microorganisms and microbiological processes. 125 While the provisions of Article 27.3 (b) surrounding exclusions of plants and animals have been a focus of intensive and ongoing attention, the practical significance of the treatment of microorganisms and microbiological processes under TRIPS has received somewhat less attention. 126 A number of so-called "TRIPS-plus" bilateral or regional trade agreements between developed countries and developing countries and regional bodies (i.e. the European Union) include references to the Budapest Treaty. A 2003 study of 45 "TRIPS-plus" agreements carried out by the non-governmental organisation GRAIN reveals 14 agreements including specific requirements for accession to the Budapest Treaty. 127 In addition, requirements for conformity with the "…highest international standards" of intellectual property protection and "no exclusions" under other "TRIPS-plus" agreements suggest that accession to the Budapest Treaty may feature in additional agreements. 128 Requirements for protection of intellectual property in relation to microorganisms may also feature in Bilateral Investment Agreements (BIAs).
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Further research may be desirable on the provisions of "TRIPS-plus" trade agreements and Bilateral Investment Agreements in relation to the patenting of microorganisms in the context of negotiation of an international regime on access to genetic resources and benefit-sharing. 130 However, the key problem in assessing the potential implications of intellectual property requirements in relation to the development of an international regime is a lack of effective methodologies to track and assess international trends in demand for intellectual property protection.
131 It is with contributing to addressing this problem with which this section of the review is primarily concerned.
One emerging approach to assessing status and trends in relation to biological and genetic material is to conduct a key word search for patent publications within the online databases of the major patent offices (i.e. the European Patent Office (EPO), the Japan Patent Office (JPO) and the United States Patent and Trademark Office (USPTO)). While valuable, searches limited to these databases do not provide a full picture of the internationalisation of demand for patent protection in relation to biological organisms and genetic material. However, the European Patent Office (EPO) has developed the esp@cenet "worldwide" database which brings together patent information from 73 patent offices, four regional patent offices and the World Intellectual Property Organisation (for the Patent Cooperation Treaty). The worldwide database contains an estimated 45 million publications of which an estimated 36,165,421 million are industrial patent publications (applications and grants) (see Annex 3). 132 As such, for the purposes of analysing global status and trends in the patenting of biological and genetic material, the esp@cenet database is the single most important source of patent data on an international level. The results of the search of the esp@cenet "worldwide" database for the key words "microorganism" and "microbe" within the title or abstract of patent publications are set out in Figure  One In considering the results of a key word search it is important to emphasise two points. First, the data generated does not provide an indicator of the number of microorganisms over which patent protection has been sought. Rather, the data provides an indicator of demand for patent protection measured in terms of publications containing key words within the title or abstract. This will also include members of "patent families" which are linked to an original (or "priority") application and thus provides an indicator of the internationalisation of demand for patent protection.
Second, the results of the search are confined to patent publications which contain the term "microorganism" or "microbe" within the title or abstract of a patent publication in English.
136 Close attention to the contents of the database reveals very significant variation in country coverage for patent publications in English ranging from zero (i.e. in the case of Brazil) to 90% or over (i.e. in the case of Canada). A review of the availability of titles and abstracts for the estimated 36,165,421 industrial patent publications within the worldwide database reveals that an average of 52% (18,806,018 publications) possess titles in English and an average of 11% (3, 978, 196 publications) possess abstracts in English. 137 As this suggests, while useful, the keyword methodology possesses significant limitations in mapping international demand for patent protection and leads to an underestimation of demand.
An alternative approach to examining trends in relation to microorganisms is through use of the International Patent Classification system (IPC) (7 th edition). 138 The International Patent Classification (IPC) system is a hierarchically organised classification system containing approximately 69,000 classifiers to categorise patent applications into sections, classes, sub-classes, groups and sub-groups. 139 In contrast with a key word methodology which depends on the availability of titles and abstracts in English, patent filings are generally awarded IPC codes to describe the claimed invention. Thus, in the case of Brazil, 99.3% of publications within esp@cenet contain IPC classifiers and while countries vary in the use of the IPC, coverage is generally over 90%. A detailed review of data coverage suggests that an average of 82% of the 36,165,421 industrial patent publications within the esp@cenet "worldwide" database, consisting of approximately 29,655,645 documents, possessed IPC classifiers (Annex 3). 140 This represents increased data capture compared with the keyword strategy of approximately 6,871,431 patent publications across the worldwide database. As such the IPC system provides a means to overcome translation difficulties in approaching international demand for patent protection and provides a much higher level of data capture than a key word search approach. In approaching this data it is important to note that an individual patent application will be assigned multiple classification codes in order to describe the claimed invention. A single application may therefore appear in the data for more than one sub-class. Any temptation to cumulate data across sub-classes should be resisted to avoid over-counting. Instead, the data provides an indicator of trends in patent claims within the relevant sub-classes relating to microorganisms and enzymes.
In summary, Table Three However, the Budapest Treaty does not include a definition of a microorganism. WIPO provides the following rationale for the lack of a definition in its guide to the Treaty:
"The term microorganism is not defined in the Treaty so that it may be interpreted in a broad sense as to the applicability of the Treaty to microorganisms to be deposited under it. Whether an entity technically is or is not a microorganism matters less in practice than whether deposit of that entity is necessary for the purposes of disclosure and whether an IDA will accept it. Thus, for example, tissue cultures and plasmids can be deposited under the terms of the Treaty, even though they are not microorganisms in the strict sense of the word." 144 This raises the question of the criteria for the classification of biological and genetic material as a "microorganism". 145 For example, would such a classification potentially apply to human or animal tissue cultures or plasmids extracted from human or animal sources? 146 In practice, the answer to this question appears to be mixed. This is revealed in Table Four which provides an overview of the types of deposits accepted by thirty-one of thirty-five IDAs under the Budapest Treaty based on information provided by WIPO. Table Four reveals that while IDAs vary significantly in terms of the categories of material they are prepared to accept, in practice the options that appear to be available are wide ranging. This suggests that closer attention to the practices of IDAs in relation to acceptance of material as 'microorganisms' for the purposes of patent disclosure could make a useful contribution to the development of an international regime on access to genetic resources and benefit-sharing. This could also perhaps usefully include clarification of whether applicants seeking to disclose material effectively "shop" for IDAs willing to accept particular kinds of material.
Turning now to the treatment of microorganisms within the International Patent Classification (IPC) system (7 th edition). 153 The main classes and sub-classes of the IPC are commonly prefaced by guidance notes for patent examiners. IPC patent class C12 (Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or Genetic Engineering) under which the main sub-classes concerned with microorganisms are located is prefaced by a note which states that: "In this class, viruses, undifferentiated human, animal or plant cells, protozoa, tissues and unicellular algae are considered as micro-organisms." 154 The notes for sub-classes C12M to C12S highlighted in Table Three, specify that: "In this subclass, unless specifically provided for, undifferentiated human, animal or plant cells, protozoa, tissues and unicellular algae are classified together with micro-organisms." 155 In practice, examination of the results of patent search results in relation to the main sub-classes of microorganisms reveals the increasing prominence of DNA and related materials within these patent sub-classes. This extends to human and animal "undifferentiated cells". Such cells include stem cells which may be collected from adults or "harvested" from embryos (either human or animal). Stem cells, particularly those derived from embryos, possess the capacity to differentiate into a wide range of other cells and are regarded as a key to the development of future therapies. In the case of human embryonic stem cells, they are also a major focus of controversy and many countries presently do not permit, or severely restrict, research involving human embryos. 156 In the case of human stem cells, the esp@cenet database contains approximately 695 publications across all years containing the words human stem cell within the title or abstract. 157 158 It should be noted that the data does not necessarily refer to per se patent claims over human embryos or their components but to publications concerning embryos and/or their components and publications relating to human embryos. Further research and analysis is desirable in order to clarify the nature of patent claims in relation to human embryos. 159 In considering the outcomes of a search of C12N using keywords and a detailed search using IPC sub-group classifiers within C12N it becomes clear that these categories include biological and genetic material that might not generally be considered to fall within the category of "microorganism". 162 This appears to be confirmed by subsequent interrogation of the esp@cenet database using the IPC classifier C12R which is employed as an indexing classifier for microorganisms based on Bergey's Manual of Determinative Bacteriology (1975) . The outcomes of this search revealed approximately 16,427 patent publications across the database. 163 On a wider level, as the results of a search for human embryo related patent claims under C12N reveals, this discussion may appear to be moving beyond the scope of existing measures under the Convention on Biological Diversity, notably the Bonn Guidelines. 164 However, it is important to note that advances in microbiology and genomics are increasingly transforming scientific understandings of genetic and biological relatedness between organisms and blurring the boundaries between the human and non-human. 165 Thus, in December of 1998 a researcher from the University of Wisconsin was issued patent number US5,843,780 under patent subgroup C12N5/06 entitled "Primate Embryonic Stem Cells" based on research with rhesus monkeys (Macaca mulatta) and the common marmoset (Callithrix jacchus). However, the patent claims were constructed to include all primate embryonic stem cells. Given that human beings are also primates the patent extends to human embryonic stem cells. 166 This patent grant was followed in March 2001 by the award of US patent 6,200,806 of the same title (under sub-groups C12N5/08 and C12N5/06) As this patent explains: "Because of the extremely close anatomical and physiological similarities between humans and rhesus monkeys, rhesus monkey true ES [Embryonic Stem] cell lines provide a very accurate in vitro model for human differentiation". 167 The patent goes on to make more specific claims relating to human embryonic stem cells based on the earlier patent.
These patent grants form part of a patent family consisting of a total of nine members, including Patent Cooperation Treaty number WO0622362 (International Publication Number). This application was originally filed in 1996 and designated 59 states on the national level, 6 states through ARIPO (the African Regional Industrial Property Organization), 7 states through EAPO (the Eurasian Patent Organisation), 16 states through the European Patent Office (EPO) and 14 states through OAPI (Organisation Africaine de la Propriété Intellectuelle). A review of the esp@cenet database reveals that this has led to subsequent applications under the European Patent Convention (publication no. EP07701256) and in Australia (publication no. AU4758496) and Canada (publication no. CA2190528).
Research and patenting in relation to human embryonic stem cells is a significant focus of debate and further consideration of these issues is beyond the scope of the present review. However, to recall Judge Lamberth's observation, this example serves to demonstrate that the issues surrounding the treatment of microorganisms under 163 Search conducted on the 2 nd of December 2004. 164 For example, Decision VI/24 para 9. establishing the scope of the Bonn Guidelines on access to genetic resources and benefit-sharing specifies that "All genetic resources and associated traditional knowledge, innovations and practices covered by the Convention on Biological Diversity and benefits arising from the commercial and other utilization of such resources should be covered by the guidelines, with the exclusion of human genetic resources." Location: <http://www.biodiv.org/decisions/default.aspx?m=cop-06&d=24>. 165 For discussion of the emerging implications of these transformations in relation to human rights and the inherent dignity of the human person see, Motoc intellectual property instruments are "…not teaspoon-sized". In particular this example suggests that the scope of an international regime and the potential role of intellectual property instruments within access and benefit-sharing arrangements will need to be considered in light of emerging scientific understanding of the relationships between organisms and in particular the realisation that significant similarities (homologies) exist in the genetic make-up of biological organisms. Growing scientific recognition of these similarities permits intellectual property claims in relation to the biological or genetic components of an individual variety or species to be extended to encompass the homologous biological and genetic components of organisms across varieties, species, genera, and classes.
One major question that emerges in relation to intellectual property claims in relation to 'microorganisms', is whether patent claims over such materials serve to promote science and innovation i.e. through product development, increased trade in goods and services, Foreign Direct Investment (FDI) and technology transfer or instead serve as vehicles for unproductive rent extraction from public and private sector researchers which may stifle research and innovation? Further consideration of this question is also beyond the scope of the present review. However, as the OECD has recently highlighted:
"The paucity of economic evaluation of the patent system is striking. Most of the changes to patent regimes implemented over the past two decades were not based on hard evidence or economic analysis. It is necessary to develop economic analysis in this domain that would inform the policy debate, giving governments a clearer view beyond the arguments put forward by pressure groups. Such analysis should rely notably on quantitative evidence…" 168 This review has sought to contribute to this process of evaluation and assessment by providing quantitative indicators and analysis of international trends in demand for patent protection in relation to microorganisms as a basis for further work. The issues raised by emerging scientific understanding of genetic relatedness (homologies) between biological organisms and wider questions surrounding the economic evaluation of the patent system are considered in greater detail in the companion review in this series 'Global Status and Trends in Intellectual Property Claims: Genomics, Proteomics and Biotechnology'.
In closing this review of available data on global trends in intellectual property claims in relation to microorganisms for the development of an international regime on access to genetic resources and benefit-sharing, five main conclusions emerge: a) Further methodological development and refinement to establish indicators on global status and trends in intellectual property claims in relation to microorganisms may be desirable in order to inform decision-making surrounding the potential role of intellectual property instruments in the development of an international regime on access to genetic resources and benefit-sharing under the Convention on Biological Diversity. In this regard it is notable that a number of organisations, such as the European Patent Office, the United States Patent and Trademark Office, the Japan Patent Office (collectively the Trilateral Offices), along with WIPO and the Organisation for Economic Co-Operation and Development (OECD) possess staff with expertise in the analysis of patent trends and patent statistics. Taking into account the substantive concerns which surround the patenting of certain types of material, i.e. DNA and stem cells, the adoption of a participatory and deliberative approach to the development of indicators may be desirable in order to promote the transparency, intelligibility and utility of indicators. In approaching any future work on patent trends in this arena the European Patent Office esp@cenet database constitutes a key resource on the international level.
b) Issues surrounding the definition of microorganisms under international intellectual property instruments are not trivial and may merit closer attention in the course of the development of an international regime directed towards the pursuit of fairness and equity in relation to sharing of the benefits arising from the utilisation of genetic resources. As part of this process, the policies and practices of International Depositary Authorities (IDAs) under the Budapest Treaty could usefully be reviewed in order to clarify the criteria employed for the acceptance of material for patent disclosure purposes. This could usefully be combined with detailed analysis of the origins and trends in patent claims over material deposited with IDAs under the terms of the Budapest Treaty. Additional work may also be desirable surrounding the treatment of microorganisms in relation to other biological and genetic material within the International Patent Classification (IPC) system. c) Limited data is presently available on trends in patenting in relation to biological and genetic material on the regional and national level. Regional and country level studies could make a valuable contribution to analysis of existing trends and the implications of intellectual property instruments for the development of an international regime across Parties to the Convention. The outcomes of the present review reveal that class C12 of the International Patent Classification system is the logical starting point for mapping trends on the regional and country level.
d) Growing scientific recognition of the significant similarities (homologies) in the biological and genetic make-up of biological organisms holds important implications for consideration of the role of intellectual property instruments in the development of an international regime on access to genetic resources and benefit-sharing. Further consideration of the significance of biological and genetic homologies between organisms across varieties, species, genera and classes may be desirable in the course of the development of the international regime. This analysis could usefully include key biological materials that extend beyond the boundaries of the lands, territories and waters of indigenous peoples and local communities, the sovereign jurisdictions of states, regions, population groups and ultimately generations, to form what may be called 'global public goods'. 169 Genes regulating biological pathways, stem cells and plant meristems may serve as potential exemplars of such 'global public goods'. e) In considering the potential role of intellectual property instruments in the development of an international regime on access to genetic resources and benefitsharing evidence based economic analysis of the costs and benefits and wider impacts of patent protection is likely to be desirable as a basis for evidence based decision-making. This analysis could potentially include consideration of the positive and negative impacts of patents in relation to science and innovation and exploration of potential alternative models to maximise research and benefitsharing while minimising externalities.
